About
Care and conscience are
the core of our corporate values
more
the core of our corporate values
19 Aug,2022
Zylox-Tonbridge maintains strong revenue and gross profit growth, including gross margin improvement driven by its platform-based strategy in 1H22
On August 15, Zylox-Tonbridge (2190.HK, “the Company”) released its 2022 interim results.
more
25 Apr,2022
Tonbridge Webinar：BGC in Transradial Neurointerventions
Chinese channal：https://live.hh-medic.com/liveview/1251English channal：https://live.hh-medic.com/liveview/1252
more
12 Apr,2022
Zylox-Tonbridge: PTA Balloon Catheter — Large Diameter Obtains Marketing Approval from NMPA
On April12, Zylox-Tonbridge (2190.HK, “the Company”) announced its PTA Balloon Catheter-Large Diameter, a product independently developed by the Company, has been granted the marketing approval by t...
more
21 Mar,2022
Zylox-Tonbridge: Approval for Commercialization of Multiple Products Enabled 544% Year-on-year Revenue Growth for the Company in 2021
Zylox-Tonbridge (2190.HK, hereinafter called the Company) announced on March 15 its first fiscal-year financial report since its IPO on Hong Kong Stock Exchange.The Company reported an ope...
more
02 Mar,2022
Approval Granted for Full Circulation of Zylox-Tonbridge H shares, Significantly Raising its Circulation Market Capitalization
Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge" or "the Company", "2190.HK") announced on February 28 that it has received approval from Hong Kong Stock E...
more
25 Jan,2022
Zylox-Tonbridge's Strategic Investment in Wire Sciences Boosts the Development of Innovative Vascular Intervention Surgical Robots
On January 17, Zylox-Tonbridge (2190.HK, “the Company”) announced the completion of its strategic investment in Wire Sciences Medical Technology（Suzhou）Co., Ltd. (“Wire Sciences”). By leveraging its own s...
more
